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second generation (anti-CCP2) and anti-mutated citrulli-
nated vimentin (anti-MCV) antibodies. Prevalence of anti-
MCV IgG (86 %), anti-carbamylated vimentin (carbVIM) 
IgG (77 %) and anti-carbamylated MCV (carbMCV) IgG 
antibodies (65 %) was higher than the classical RF IgM 
(60 %) and anti-CCP2 IgG (52 %) in this RA cohort. Of 
note, smoking status was associated with positive IgG anti-
body reactivity against CCP2 in 75.0 % and against MCV 
in 90 % of patients. Furthermore, IgM antibody response 
against carbMCV and carbVIM was observed in 80 and 
90.0 % of smokers, respectively. Due to a high sensitivity 
of the IgM antibody isotype of anti-carbVIM of 85.2 %, the 
combination of ACPA with anti-carbVIM IgM provided the 
best diagnostic performance so far achieved in a RA cohort 
of this ethnic origin. We demonstrate a high prevalence of 
anti-carbVIM antibodies and correlation with smoking in 
Latin American (Cuban) RA patients. Anti-carbVIM IgM 
represents an useful marker in ACPA-negative patients and, 
in combination with ACPA IgG assays, optimizes the strat-
egy for autoantibody testing.
Keywords Rheumatoid arthritis · Anti-mutated 
citrullinated vimentin · Citrullinated vimentin · 
Carbamylated vimentin · Anti-cyclic citrullinated peptides
Introduction
Posttranslational modification (PTM) of self-antigens is 
a key characteristic of rheumatoid arthritis (RA) [1–5]. 
During the last decade, especially the relevance of protein 
citrullination has been in the focus of intensive research. 
Finally, anti-citrullinated protein antibodies (ACPA) 
were included as a serological marker in the new Ameri-
can College of Rheumatology/European League against 
Abstract Smoking produces substances that activate pro-
inflammatory, prothrombotic and vasoconstrictive media-
tors via posttranslational carbamylation of proteins. As 
a new consequence of carbamylation, induction of anti-
carbamylated autoantibodies were observed in rheuma-
toid arthritis (RA) patients, sometimes prior to onset of 
the disease. The overall aim of this study was to charac-
terize the reactivity of different isotypes of autoantibod-
ies against carbamylated antigens of vimentin in relation 
to established rheumatoid factor (RF), anti-citrullinated 
protein antibodies (ACPA) and markers of disease activ-
ity in a so far largely uncharacterized population of Latin 
American (Cuban) patients with RA. Antigenic properties 
of carbamylated vimentin as well as vimentin peptides 
were analyzed in 101 patients with RA, 50 disease controls 
and 51 healthy controls. The diagnostic performance was 
compared with established commercial ELISA rheuma-
toid factor, anti-cyclic citrullinated peptide antibodies of 
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Rheumatism (ACR/EULAR) classification criteria for RA 
[6]. The majority of studies showed that ACPA can dis-
criminate between RA and other arthropathies with high 
specificity. They may allow early identification of patients 
who require more aggressive therapy [7–10]. One of the 
most common antigenic targets employed for ACPA testing 
are second-generation cyclic citrullinated peptides (CCP2) 
with higher specificity and sensitivity than IgM rheumatoid 
factor (RF) test [7, 8]. However, to improve RA diagnostic, 
the different markers are used in combinations [11].
Nevertheless, there is still a serologic gap with seron-
egative patients in established RA and more emphasis 
was placed on the identification of novel markers. In this 
context, several citrullinated proteins have been identified 
in the synovium of inflamed joints of RA patients includ-
ing fibrinogen, enolase, fibronectin, type II collagen and 
vimentin [9]. All of them are considered potential relevant 
candidates to trigger ACPA production in genetically sus-
ceptible individuals.
The first anti-citrullinated vimentin antibodies detected 
in RA patients were termed anti-Sa and are characterized 
by high specificity but low sensitivity [9, 12]. Bang et al. 
[13] identified an antigenic mutated isoform of vimentin, 
which was the basis for the introduction of the anti-mutated 
citrullinated vimentin assay (anti-MCV). Several studies 
have shown that the anti-MCV assay is a useful diagnos-
tic tool for RA [9, 14, 15]. However, due to the overlap 
of ACPA specificities the diagnostic issue of seronegative 
patients was not solved.
Recently, carbamylation of lysine residues to form 
homocitrulline, another PTM, was described as a key 
mechanism triggering inflammatory responses by gener-
ating neoepitopes, which are targeted specifically by anti-
carbamylated protein antibodies (anti-carbP) from sera 
samples of RA patients. The presence of anti-carP anti-
bodies in RA patients is associated with more severe joint 
damage and was identified prior to the onset of the specific 
RA symptoms. In contrast to citrullination, carbamylation 
is a nonenzymatic PTM, related to aging and lifestyle such 
as smoking status [3–5]. Of note, smoking is responsible 
for high rates of preventable mortality in Cuba. Of deaths 
recorded in 1995 and 2007, 15 and 18 % of preventable 
deaths were attributed to smoking, respectively [16].
Latin America RA cohorts have been incompletely 
characterized so far, since in most studies only the anti-
CCP2 assay has been used [17–20]. To our knowledge, 
there are no published studies with Cuban patients eval-
uating response to different isotypes of ACPA or anti-
carbP antibodies. However, this population is unique due 
to the mixed ethnical and special environmental back-
ground. Therefore, we evaluated the reactivity of different 
isotypes of autoantibodies against citrullinated and carba-
mylated antigens derived from the sequence of vimentin 
and compared that with RF and anti-CCP2 in a well-char-
acterized cohort of Cuban patients with RA. Furthermore, 
correlation of autoantibodies titers with disease activity 




In this study, 101 patients from the National Center for 
Rheumatology in Cuba fulfilling the ACR classification cri-
teria for RA [6] and 50 disease controls from the National 
Center of Medical Genetic were recruited: 11 undifferen-
tiated arthritis, 10 systemic lupus erythematosus, 7 mixed 
connective tissue disease, 3 psoriatic arthritis, 2 spondy-
loarthritis, 2 autoimmune myositis, 3 systemic sclerosis, 
1 polymyalgia rheumatica, 1 Sjögren’s syndrome, and 10 
viral hepatitis-related arthralgia. Furthermore, 51 healthy 
donors served as controls (Havana Provincial Blood 
Donation Center). Data collection and clinical examina-
tions were performed by a rheumatologist. Patients with 
RA were classified according to disease duration as early 
(<12 months) or established RA (>12 months). Clinical 
characterization of patients with RA is shown in supple-
mentary Table S1 including disease activity score using 28 
joint counts (DAS28) based on erythrocyte sedimentation 
rate (ESR). None of the patients with RA was treated with 
a biological therapy.
The study was approved by the Medical Ethics Com-
mittee of the National Center of Medical Genetic and 
the National Center of Rheumatology in Cuba. Written 
informed consent was obtained from all patients.
Detection of RF, anti‑CCP2 and anti‑MCV 
IgG antibodies by quantitative enzyme‑linked 
immunosorbent assay (ELISA)
Profiling of autoantibodies was performed at the research 
laboratory of the Department for Rheumatology and Clini-
cal Immunology at the Charité-University Hospital in Ber-
lin. Anti-MCV IgG antibodies and RF of different isotypes 
(IgM, IgG and IgA) were measured using commercially 
available ELISA kits (Orgentec Diagnostika, Germany), 
with a cutoff point at 20 U/mL. Detection of anti-CCP2 
antibodies by ELISA was performed according to the man-
ufacturer’s instructions (MEDIPAN, Germany) with the 
cutoff point at 30 U/mL as recommended.
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Detection of antibodies against citrullinated 
and carbamylated antigens of vimentin
Human recombinant vimentin, cloned, expressed and puri-
fied as described previously [13], was used to generate the 
citrullinated and carbamylated isoforms.
Each arginine residue from the vimentin protein was 
converted into a citrulline residue in vitro by rabbit muscle 
peptidylarginine deaminase (PAD) (Sigma; 40 U of PAD 
per milligram of vimentin) after incubation for 3 h at 55 °C 
in a buffer containing 0.1 M Tris–HCl (pH 7.6), 10 mM 
CaCl2, and 5 mM dithioerythritol. After termination of the 
reaction by adding EGTA (pH 8.0; final concentration of 
50 mM), the samples were separeted by electrophoresis and 
noncitrullinated and citrullinated proteins were detected 
by immunoblotting with commercial anti-vimentin (H-84; 
Santa Cruz Biotechnology Inc., Heidelberg, Germany), and 
using an ACPA sera pool from the previously published 
cohort to verify the citrullination [21].
Carbamylated vimentin (carbVIM) and carbamylated 
mutated citrullinated vimentin (carbMCV) were gener-
ated after treatment of 1 ml of vimentin (1.7 mg/ml) with 
500 mM potassium cyanate for 2 h at 37 °C. Excess of 
chemical reagents were removed from both vimentin iso-
forms, with desalting mini columns according to manu-
facturer’s instructions (zeba Spin, Thermo Scientific, Ger-
many). Carbamylated samples were digested with trypsin, 
and the mass spectra of the tryptic peptides were measured 
with a MALDI-TOF mass spectrometer (Ultraflex III TOF/
TOF, Bruker Daltonics, Proteosys AG, Mainz, Germany). 
The m/z values of the peptides were compared with protein 
databases (NCBI, Mascot browser), and as a result, the tryp-
tic peptides were determined to be assigned proteins (pep-
tides mass fingerprint, PMF). In addition, MS/MS sequenc-
ing were (with the Ultraflex III TOF/TOF) performed on 
selected peptides. Calculation of relative amounts of lysine 
coating solution of modified protein in 50 mM carbonate 
buffer, pH = 9.0 were incubated overnight at 4 °C (100 μl/
well, Costar microtiter plates). Possible over pluses of pep-
tides/antigens were eliminated by washing the cavities with 
200 µl/well of 0.1 % Tween 20 in phosphate-buffered saline 
and finally blocked with a 1 % bovine serum albumin solu-
tion in phosphate-buffered saline. Finally, flicking and slap-
ping removed any residual solution.
For ELISA, 1:100 diluted serum samples (sample buffer, 
phosphate-buffered saline, plus 1 % bovine serum albumin 
and 0.05 % Tween-20) were incubated for 30 min (100 μl/
well), washed three times (300 μl/well), horseradish per-
oxidase conjugated antihuman IgG, IgM, IgA (Dianova, 
Hamburg, Germany) was added and incubated for 15 min 
(100 μl/well). Visualization was done by incubation with 
3,3′,5,5′-tetramethyl benzidine (TMB) substrate for 15 min 
(100 μl/well), and the reaction was terminated by add-
ing 100 μl stop solution (0.5 mol/l H2SO4) to each well. 
Optical densities (OD) were measured at 450/620 nm in 
a BioTek micro well photometer (Synergy HT, BioTek 
Instruments Inc, USA) and transformed to units per milli-
liter using a 4-parameter-fit titration curve.
All steps were carried out at room temperature. Each 
serum sample was tested in duplicate. The distribution of 
OD of antibodies against modified peptides in healthy indi-
viduals (n = 112) was assessed, and values >98th percen-
tile of the healthy controls were considered positive for all 
antibodies.
Antibodies against modified vimentin peptides were 
determined according to the recently published procedure 
[21]. Briefly, a vimentin peptide sequence (used peptide 
sequence is bold and underlined in the shown N-terminal 
vimentin sequence) known to be preferential recognized by 
autoantibodies from RA patients was used for designing a 
panel of modified peptides [22, 23].
and homocitrulline residues in each peptide was done by 
comparison with the quantitated synthetic peptide standard. 
Representative sequences and calculation of two peptides 
were shown: Peptide 101–113, Lys104 = 83 % and peptide 
187–196, Lys189 = 82 % carbamylation.
MCV, carbVIM and carbMCV were coated on micro-
titer plates as earlier described by Bang et al. [21] and in 
accordance with the general protocol for the Orgentec 
immunometric enzyme immunoassay. Briefly, 1 µg/ml 
1 MSTRSVSSSS YRRMFGGPGT ASRPSSSRSY VTTSTRTYSL GSALRPSTSR
51 SLYASSPGGV YATRSSAVRL RSSVPGVRLL QDSVDFSLAD AINTEFKNTR
The peptide sequence: NH2-GGVYATXSSAVR-OH 
was used as “native vimentin” reference peptide P62. The 
glycine residue in position 2 was mutated into an arginine 
amino acid residue to increase the sensitivity of the citrul-
linated peptide. The designated position X was substituted 
either with the citrulline (citrullinated) or with the homoc-
itrulline (carbamylated) amino acid residue. The N-ter-
minal biotinylated peptides, identical in length (12 amino 
acids) and composition, but differing only in position 7 
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were synthesized (JPT Peptide Technologies GmbH, Ber-
lin, Germany; details are illustrated in supplementary figure 
S2).
Coating and assay performance were done as described 
above, with the following amendments: Only 0.5 µg/ml 
biotinylated peptide was mixed in phosphate-buffered and 
coated. Possible over pluses of peptides was eliminated by 
washing the cavities with 200 µl/well of 0.05 % Tween 20 
in phosphate-buffered saline. Finally, flicking and slapping 
removed any residual solution.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
software version 6.0 and Epidat 3.1. Data were expressed 
as median and interquartile ranges between the 25th quar-
tile and 75th quartile for continuous variables and as fre-
quency and percentage for categorical variables. The non-
parametric Mann–Whitney U test was applied when two 
groups were compared. Sensitivity, specificity, predictive 
values, Youden index (YI) and areas under curve (AUC) of 
Receiver Operating Characteristic Curve (ROC) analysis 
were determined. The correlation analysis was performed 
according to Spearman’s test. For association analysis χ2 
and odd ratios (OR) were calculated. p values <0.05 were 
considered significant.
Results
Generation of recombinant citrullinated and/or 
carbamylated vimentin isoforms
Tobacco smoke contains pathogenic ingredients, i.e., 
hydrocyanic acid (OCN-), which is normally rapidly 
detoxified by transsulfuration forming thiocyanate ions 
(-SCN). These thiocyanate ions can be oxidized in vivo and 
subsequently form cyanide in inflammatory loci through 
the action of hydrogen peroxide plus myeloperoxidase 
(MPO) from neutrophils or eosinophil peroxidase (EPO). 
Therefore, we established the procedure for generation of 
carbamylated vimentin with the nonenzymatic incubation 
of potassium cyanate (KCN). As shown in supplementary 
figure S5, nearly quantitative carbamylation (approximately 
80 %) of vimentin could be verified by amino acid analysis 
using MALDI-TOF mass. Furthermore, no additional mod-
ifications of other amino acid residues were detectable indi-
cating that only homocitrulline residues were formed from 
lysine residues after KCN- exposure.
The procedure of vimentin citrullination was established 
with a very low amount of PAD as described previously 
[13]. Cross-reaction with the PAD enzyme was excluded as 
shown by Western blot analysis in supplementary figure S3. 
To generate a double-modified vimentin isoform, a sequen-
tial procedure was established by citrullinating the mutated 
vimentin in a first step, followed by carbamylation.
The efficiency of each step was verified by SDS-PAGE 
electrophoresis with coomassie brilliant staining showing 
a shift to higher molecular weight for the citrullinated iso-
form and a backward shift after additional carbamylation 
(supplementary figure S4). To confirm that the migration 
shift was due to citrullination, blots containing the same 
samples were analyzed using affinity purified anti-citrulline 
antibody from our previously study (supplementary figure 
S2 B) [21]. The results showed that the citrullinated and the 
citrullinated plus carbamylated isoform cross-react with the 
purified antibodies. These results are in agreement with the 
distinct modification positions for citrullination (modified 
arginine R) and carbamylation (modified lysine K), as illus-
trated in supplementary figure S6.
Fig. 1  Relative frequency of 
antibodies against citrullinated 
and carbamylated sequences 
of vimentin, anti-CCP2 and 
RF in patients with early and 
established RA. RA rheumatoid 
arthritis, RF rheumatoid fac-
tor, CCP2 cyclic citrullinated 
peptides of second generation, 
MCV mutated citrullinated 
vimentin, carbVIM carbamyl-
ated vimentin, carbMCV carba-
mylated mutated citrullinated 
vimentin, CCP VIM cyclic 
citrullinated peptides of vimen-
tin, Ig immunoglobulin. Cutoff 
value of anti-CCP2 was 30 U/
mL according to manufacturer’s 
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Autoantibodies reactivity against RF and anti‑CCP2
By using regular assays for the detection of RF and anti-
CCP2, frequencies of RF IgM (48.5 %), RF IgA (60.6 %) 
and RF IgG (45.5 %) were higher than anti-CCP2 (39.4 %) 
antibodies in patients with early RA. In patients with estab-
lished RA, prevalence of RF IgM (66.0 %) and RF IgA 
(73.5 %) was also higher than anti-CCP2 (58.8 %) followed 
by RF IgG (51.5 %). The most frequently detected stand-
ard autoantibody in this cohort was RF IgA (Fig. 1). Of 
note, higher autoantibody titers were observed in patients 
with established RA (Fig. 2b) compared to early disease 
(Fig. 2a).
Autoantibodies reactivity against carbamylated 
and citrullinated antigens based on the sequence 
of vimentin
The reactivity against carbamylated and citrullinated vimentin 
antigens showed a higher prevalence compared to anti-CCP2 
and RF in Cuban patients with RA (Fig. 1). Interestingly, 
patients with early RA showed highest frequencies for anti-
carbMCV IgM (90.9 %) and anti-carbVIM IgM (87.9 %) fol-
lowed by anti-MCV IgG (81.8 %). In patients with established 
RA, these antibodies were also predominant with the highest 
prevalence for anti-MCV IgG (88.2 %) followed by anti-carb-
VIM IgM (83.8 %) and anti-carb MCV IgM (76.5 %).
Fig. 2  Median of titers of 
antibodies against citrullinated 
and carbamylated sequences of 
vimentin, anti-CCP2 and RF 
in RA patients. a Early RA. b 
Established RA. RA: rheuma-
toid arthritis. RF rheumatoid 
factor, CCP2 cyclic citrullinated 
peptides of second generation, 
MCV mutated citrullinated 
vimentin, carbVIM carbamyl-
ated vimentin, carbMCV carba-
mylated mutated citrullinated 
vimentin, CCP VIM cyclic 
citrullinated peptides of vimen-
tin. Ig: immunoglobulin. Cutoff 
value of anti-CCP2 was 30 U/
mL according to manufacturer’s 
instruction, and for others assay 
was 20 U/mL
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Patients with RA showed also higher frequencies of IgG 
autoantibodies against the carbamylated peptide of vimen-
tin HC52, compared to RF IgM, RF IgG and anti-CCP2 
(Fig. 1). However, these frequencies were lower than those 
observed for anti-carbVIM IgM. Thus, reactivity against 
citrullinated and carbamylated isoforms of vimentin was 
higher than those observed against modified peptides. 
Overall, reactivity against newly found citrullinated and 
carbamylated sequences of vimentin was more frequent 
with IgM and IgG antibodies than with IgA.
Table 1  Demographic and clinical characteristics of RA patients, according to presence of anti-MCV IgG antibodies
RA rheumatoid arthritis, n number of patients, DAS28 disease activity score, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HAQ 
Health Assessment Questionnaire Index, m median, n number of patients, IQR interquartile range
* Significant differences between anti-MCV IgG positive and negative groups on median (p < 0.05)
Assay Early RA (n = 33) Established RA (n = 68)
MCV+ (n = 27) MCV− (n = 6) MCV+ (n = 60) MCV− (n = 8)
F, n (%) 19 (70.4) 5 (83.3) 52 (86.7) 6 (75.0)
Age in years, m (IQR) 50 (41–59) 43 (32–48) 52 (43–51) 57 (48–71)
Smoker, n (%) 7 (25.9) 1 (16.7) 11 (18.3) 1 (12.5)
Disease duration in years, m (IQR) 1.0 (0.5–1.0) 0.9 (0.8–1.0) 6.0 (3.0–11.0) 11.0 (5.0–16.2)
DAS28, m (IQR) 5.3 (4.2–6.3) 3.3 (3.0–4.9) 5.1 (3.8–5.9) 5.0 (4.5–5.7)
Remission: DAS28 ≤ 2.6; n (%) 1 (3.7) 0 6 (10.0) 0
Low: DAS28 > 2.6 and ≤ 3.2, n (%) 2 (7.4) 3 (50.0) 7 (11.7) 5 (62.5)
Moderate: DAS28 > 3.2 and ≤ 5.1, n(%) 9 (33.3) 1 (16.7) 19 (31.7) 5 (62.5)
High: DAS28 > 5.1, n (%) 15 (55.6) 2 (33.4) 28 (46.7) 3 (37.5)
HAQ, m (IQR) 0.60 (0.44–0.81) 0.28 (0.25–0.24) 0.75 (0.25–1.37) 1.06 (0.81–1.41)
ESR, m (IQR) 44.0 (25.5–64.5) 16.0 (13.5–21.5) 29.0 (16.0–54.2) 26.0 (16.3–62.8)
CRP positivity, n (%) 21 (77.8) 1 (16.7) 36 (60.0) 2 (25.0)
Table 2  Comparison of level and frequencies of positivity of autoantibodies according to presence of anti-MCV IgG
RA rheumatoid arthritis, MCV mutated citrullinated vimentin, CarbVIM carbamylated vimentin, CarbMCV carbamylated mutated citrullinated 
vimentin, RF rheumatoid factor, CCP2 cyclic citrullinated peptides of second generation, Ig immunoglobulin, n number of patients, m median, 
IQR interquartile ranges
* Significant differences between anti-MCV IgG positive and negative groups on antibodies titers (p < 0.05)
Assay Early RA (n = 33) Established RA (n = 68)
MCV+ (n = 27) MCV− (n = 6) MCV+ (n = 60) MCV− (n = 8)
RF IgM+, n (%) 16 (48.5) 0 43 (63.2) 0
RF IgM, m (IQR)* 27.2 (10.5–303.2) 6.9 (2.3–12.3) 66.8 (15.3–316.7) 4.35 (0–21.9)
CCP2 +, n (%) 13 (39.3) 0 40 (58.8) 0
CCP2, m (IQR) * 22.6 (4.1–2100.0) 4.5 (3.2–7.1) 163.7 (79–1772.0) 3.8 (1.9–5.6)
CarbVIMIgM+, n (%) 24 (72.7) 5 (83.3) 51 (75.0) 6 (75.0)
CarbVIMIgM, m (IQR) 63.6 (10.1–126.8) 43.9 (25.2–97.7) 55.1 (30.6–109.5) 31.0 (20.7–65.6)
RF IgM−/CCP2−, n (%) 10 (30.3) 6 (100) 15 (22.1) 6 (75.0)
RF IgM +/CCP2 +, n (%) 12 (36.4) 0 38 (55.9) 0
RF IgM, IgG, IgA−/CCP2−, n (%) 6 (18.2) 5 (83.3) 12 2 (25.0)
RF IgM, IgG, IgA +/CCP2 +, n (%) 10 (30.3) 0 27 (45.0) 0
RF IgM, IgG, IgA +/CCP2−, n (%) 2 (6.1) 0 4 (5.9) 0
CCP2−/CarbVIMIgG +/HC52 IgG +, n (%) 1 (3.1) 1 (16.7) 10 (7, 16) 2 (25.0)
CarbVIMIgM +/carbMCVIgM+, n (%) 24 (72.7) 5 (83.3) 47 (69.1) 5 (62.5)
CarbVIMIgM −/carbMCVIgM−, n (%) 2 (6.1) 0 9 (13.2) 2 (25.0)
CarbVIMIgM +/carbMCVIgM +/RF IgM +/CCP2 +, n (%) 12 (36.4) 0 30 (44.1) 0
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Demographic, clinical characteristics and autoantibody 
reactivity of RA patients, depending on the positivity 
for anti‑MCV IgG
Patients with anti-MCV IgG antibodies showed no statis-
tical difference in demographic characteristics compared 
to the seronegative cohort (Table 1). Nevertheless, clinical 
phenotypes were different in these two groups of patients 
with a higher rate of low DAS28 and remission achieved in 
anti-MCV negative patients (p = 0.0048, OR 0.2, 95 % CI 
0.6–0.1)
By comparing the titers of the RF IgM, anti-CCP2 and 
anti-carbVIM IgM, we observed higher values for anti-
MCV IgG positive compared to negative patients (Table 2). 
Differences were only significant for RF IgM and anti-
CCP2 antibodies in both early (p < 0.01) and established 
(p < 0.05) RA patients. A high coincidence rate of autoan-
tibodies was especially observed for combinations of anti-
carbVIM IgM and anti-MCV IgG in patients with early 
(up to 72.7 %), and established RA (up to 75.0 %). Out of 
25 patients tested negative for all isotypes of RF and anti-
CCP2, 18 were positive for anti-MCV IgG (Table 2).
From the patients with negative results for anti-CCP2, 
anti-carbamylated antigens IgG antibodies were detectable 
in 13.9 and 3.0 % of cases against the protein and peptide, 
respectively. Concurrent seropositivity for anti-carbVIM 
IgM, anti-carbMCV IgM, anti-MCV IgG, RF IgM and anti-
CCP2 was detectable in 12.0 % of samples from patients 
with early RA and in 30.0 % of patients with established 
RA (Table 2). Of note, all anti-MCV seronegative patients 
were also negative for RF IgM and anti-CCP2 assays in 
both early and established RA.
In anti-MCV IgM-negative patients, determination of 
anti-carbVIM IgM identified an additional proportion of 
15.2 % of positive early RA cases and 8.8 % of patients 
with established disease. Combination of these two assays 
was able to detect autoantibodies in 97 % of patients with 
early or established RA (Fig. 3). In contrast, combination 
of anti-CCP2 and anti-carbVIM IgM assay was able to 
detect autoantibodies at a lower frequency.
Diagnostic value of anti‑MCV IgG, anti‑carbVIM IgM 
and anti‑CCP2 assays
The diagnostic sensitivity and specificity of each assay 
using different cutoffs and ROC analysis are shown in 
Table 3. Optimal cutoff value, based on the highest pos-
sible sensitivity and specificity, using YI, was the same as 
Fig. 3  Cumulative positive 
results of ACPA and anti-
carbVIMIgM assays in patients 
with early and established RA. 
RA rheumatoid arthritis, MCV 
mutated citrullinated vimen-
tin, carbVIM carbamylated 
vimentin, Ig immunoglobulin. 
Positive results were considered 
according to the manufacturer’s 
instructions
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recommended by the manufacturer for anti-MCV assay 
IgG; for anti-carbVIM IgM cutoffs of 20 and 30 U/mL 
showed very similar balance of sensitivity and specificity 
and for anti-CCP2 optimal cutoff was 40 U/mL.
A higher sensitivity was observed by using combination 
of assays, when positive results were considered for at least 
one assay anti-carbVIM IgM or anti-MCV IgG (97.0 %). 
For combination of anti-carbVIM IgM or anti-CCP2, the 
sensitivity was 91.1 %. Interestingly, specificity observed 
for combination of anti-carbVIM IgM and anti-CCP2, 
when positive results were considered for both assays, was 
higher (99.1 %) than specificity observed for combination 
of anti-carbVIM IgM and anti-MCV IgG (96.0 %). The 
highest possible sensitivity and specificity balance using 
YI was observed for combination of assays, when positive 
results were considered for at least one of both: anti-carb-
VIM IgM and anti-CCP2 assays. Of note, the AUC of ROC 
analysis was superior for anti-carbVIM IgM assay. The 
reactivity of anti-MCV IgG, anti-carbVIM IgM and anti-
CCP2 assays in disease and healthy controls are shown in 
supplementary table S7.
In patients with established RA, a weak correlation 
with DAS28 was only observed for anti-CCP2 assay (sup-
plementary table S8). Low DAS28 and remission were 
more frequently achieved in anti-CCP2-negative patients 
(p = 0.0091, OR 0.2, 95 % CI 0.7–0.1).
Interestingly, 75.0 % of patients positive for anti-CCP2, 
90 % of patients positive for anti-MCV, 80 % of patients 
positive for anti-carbMCV IgM and 90.0 % of patients 
positive for anti-carbVIM IgM were smokers. A signifi-
cant association was only evident for smoking status and 
presence of anti-CCP2 (p = 0.0216, OR 3.9, 95 % CI 
1.3–11.9), for CRP and RF IgM (p = 0.0001, OR = 6.4, 
95 % CI 2.5–16.8) as well as anti-MCV IgG (p = 0.0307, 
OR = 5.3, 95 % CI 1.3–21.3) and anti-CCP2 (p = 0.0000, 
OR = 5.8, 95 % CI 2.4–14.1).
The Spearman rank correlation test was significant 
(p < 0.05) for anti-CCP2, anti-MCV IgG as well as anti-
carbVIM IgM antibodies and RFIgM in both early and 
established RA patients. Anti-CCP2, anti-MCV IgG and 
anti-carbVIM IgM showed positive correlation with ESR in 
early RA patients (supplementary table S8).
Discussion
The most interesting finding in our study was the high fre-
quency of antibodies against citrullinated and carbamyl-
ated antigens of vimentin, as well as the good diagnostic 
performance of the anti-carbVIM IgM assay in Cuban 
patients with RA. This observation is of importance not 
only for improved diagnostic procedures, but also for a bet-
ter understanding of the pathogenesis based on the different 
ethnic and genetic background. Adequate identification of 
seropositive patients and potential measurement of all three 
isotypes could improve the routine diagnostic procedures in 
RA, to close the gap of seronegative patients and to iden-
tify those with severe outcome [11]. It has been stated that 
patients with all isotypes of RF have a very high likelihood 
of been diagnosed with RA, similar to patients with simul-
taneous presence of RF IgM, RF IgA and anti-CCP2 anti-
bodies [11]. In agreement with this observation, very few 
patients were negative for all RF isotopes and ACPA in our 
study.
According to our results, the frequency of RF IgM in 
the Cuban patients was similar to another study that used 
ELISA, since seropositivity of RF has been reported to be 
close to 50 % in Latin America [17]. Although Kokuina 
Table 3  Diagnostic value of 
ACPA and anti-carbVIMIgM 
assays using Receiver Operating 
Characteristic Curve analysis
MCV mutated citrullinated vimentin, carbVIM carbamylated vimentin, Ig immunoglobulin, Se sensitivity, 
Sp specificity, PPV positive predictive value, NPV negative predictive value, YI Youden index
Assay, area under curve (confidence interval) Cutoff (U/mL) Se Sp PPV NPV YI
Anti-carbVIMIgM, 0.9111 (0.8722–0.9501) 20 85.2 90.1 89.6 85.9 0.75
30 78.2 96.3 96.3 81.8 0.75
40 59.4 100 100 71.7 0.59
Anti-MCV IgG, 0.8479 (0.7959–0.8999) 20 86.1 75.3 77.7 84.4 0.61
30 68.3 87.1 84.1 73.3 0.55
40 60.4 92.1 88.4 69.9 0.52
Anti-CCP2, 0.7537 (0.6953–0.8122) 20 54.5 92.1 87.3 66.9 0.47
30 52.5 95.1 91.4 66.9 0.48
40 51.5 98.1 96.3 66.9 0.50
Anti-carbVIMIgM and anti-MCV IgG 20 74.2 96.0 94.9 78.9 0.70
Anti-carbVIMIgM or anti-MCV IgG 20 97.0 69.3 76.0 95.9 0.66
Anti-carbVIMIgM and anti-CCP2 20/40 46.5 99.0 97.9 64.9 0.46
Anti-carbVIMIgM or Anti-CCP2 20/40 91.1 89.1 89.3 90.9 0.80
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et al. described the presence of RF in the Cuban popu-
lation at higher frequencies (84 % in established and 
67 % in early RA) by using immunoturbidimetry [24], it 
has to be considered that these assay techniques are not 
directly comparable to ELISA with respect to obtained 
isotypes, titers and specificity [19, 20]. Interestingly, 
our frequencies for RF IgA were higher than RF IgM in 
Cuban patients. While other authors mentioned preva-
lence rates of RF IgA close to 42.5 % in early and 37.5 % 
in established RA in another country of Latin America 
[15], we observed 60.6 % in early and 73.5 % in estab-
lished disease. This finding is of special interest since RF 
IgA has been associated with severity of the disease and 
was reported to predict the development of RA [11]. The 
observed higher frequencies of RF IgA can be partially 
explained by the fact that almost 50 % of Cuban patients 
in our cohort had high disease activity (DAS28 > 5.1) 
and about 80 % of patients had moderate or high disease 
activity (DAS28 > 3.2).
Although the pathogenesis of RA has not yet been elu-
cidated, growing evidence supports the involvement of an 
immune response against modified antigens. Since citrul-
linated peptides can bind with a higher affinity to human 
leukocyte antigen (HLA) DR alleles encoding the so-called 
shared epitope, they are efficiently presented to the immune 
system and can lead to activation of CD4+ T cell breaking 
immunological tolerance to self-antigens [2].
Of note, the prevalence of anti-CCP2 antibodies was not 
as high as expected for early RA in our study. However, 
prevalence of these antibodies has been reported between 
48 and 85 % in other cohorts in Latin America [17–20]. 
These differences can be due to genetic factors, environ-
mental background or the commercial assay used [2, 7, 8]. 
Genetic alterations that are likely to be influenced by envi-
ronmental factors can lead to the production of ACPA [2]. 
Unfortunately, there are no data available on the frequency 
of the shared epitope in the Cuban population.
As an ubiquitous expressed auto-antigen, vimentin might 
be of special relevance in triggering ACPA production. 
Vimentin immunization can induce an arthritogenic process 
as well as a specific T cell response in mice. In this context, 
an association of an immune response against vimentin and 
certain human leukocyte antigen (HLA)-DR alleles encod-
ing the “shared epitope” has been reported. Moreover, the 
presence of citrullinated vimentin in immuno-complexes 
of synovial fluid of RA patients with ACPA and the high 
specificity of anti-citrullinated vimentin antibodies further 
emphasize their role in the pathogenesis of RA [9].
Previous studies in Mexico have reported a prevalence 
of anti-MCV antibodies in 81.0 % [14] and 69.7 % of cases 
[25]. However, both studies did not differentiate between 
patients with early or established diseases. In our study, 
we observed high frequencies of this autoantibody in both 
subgroups. With respect to the study by Diaz-Toscano et al. 
[14] showing sensitivity of 81 % and specificity of 94 % for 
anti-MCV assay, we observed a higher sensitivity but lower 
specificity in our cohort.
The B cell ACPA response is dependent on T cell acti-
vation after the first antigen contact for production of the 
IgM isotype and followed by the production of IgG after 
repeated antigen exposure. Usually, the half-life of IgM is 
short, and memory B cells against T-cell-dependent pro-
tein antigens typically produce IgG and not IgM antibod-
ies. One explanation for the persistent reactivity of IgM 
and IgG ACPA is that some citrullinated antigens are able 
to activate new B cells despite concurrent recognition by 
IgG ACPA. In this context, it has been observed that several 
defined citrullinated antigens are recognized only by IgG 
ACPA, whereas others are also recognized by IgM ACPA 
[26]. In our cohort, the prevalence of anti-MCV IgG was 
higher than anti-MCV IgM and anti-MCV IgA supporting 
the usefulness of IgG ACPA for diagnostic purposes.
Initial evidence suggests that carbamylation of antigens 
is also involved in the pathogenesis of RA. Carbamylated 
proteins induce the chemotaxis and activation of CD4+ T 
cells with a strong antibody response. This could be the first 
phase of autoreactivity in RA subsequently leading to the 
local recognition of citrullinated peptides within the joints 
and to the development of erosive arthritis [27, 28]. Shi 
et al. [3, 4] identified anti-carbP antibodies in the serum of 
RA patients that predict disease progression in ACPA-neg-
ative patients. Also Stoop et al. [27] observed an immune 
response against carbamylated antigens in an arthritis ani-
mal model induced by collagen before disease onset. In 
agreement with Shi et al. [3], we also found anti-carbVIM 
and anti-carbMCV antibodies in both ACPA-positive and 
ACPA-negative patients with RA. In subsequent studies, it 
would be of interest to clarify, whether antibodies against 
carbamylated antigens can also predict the development of 
RA independently of the presence of ACPA [4].
According to our observations, the anti-carbVIM assay 
was able to detect more anti-CCP2 seronegative patients 
in early than in established RA. These observations are in 
agreement with the data obtained by Stoop et al. [27], indi-
cating that the tolerance to carbamylated proteins, in con-
trast to the response to citrullinated proteins, is easily bro-
ken and that arthritis boosts the immune response against 
these proteins explaining the phenomenon that anti-carbP 
antibodies already appeared before disease onset [27].
There is growing evidence that diagnostic performance 
in RA patients could be increased by using more than 
one assay [8, 29]. In fact, we observed that the sensitiv-
ity could be increased by using both anti-MCV IgG and 
anti-carbMCV IgM or anti-CCP2 and anti-carbMCV IgM 
assays. Such a very high sensitivity by combination of 
tests is extremely relevant and could significantly facilitate 
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early diagnosis of RA. Although reactivity against modi-
fied vimentin was predominant, the modified peptides were 
also recognized as autoantigens by antibodies from patients 
with early and established RA.
Several studies have shown a stronger correlation of anti-
MCV levels with clinical parameters compared with anti-
CCP2 levels [2, 30]. Other authors suggest that anti-carbP 
antibodies can have clinical value in the prediction of RA, as 
well as for disease progression [3, 27, 31]. We found similar 
correlations between anti-MCV IgG, anti-CCP2 and anti-car-
bVIM IgM antibodies with ESR in patients with early RA. It 
is of note that we observed a weak correlation between anti-
CCP2 antibodies and DAS28 in patients with established 
disease in contrast to other studies [32, 33]. Furthermore, 
seronegative RA patients for anti-CCP2 or anti-MCV were 
more frequently in low disease activity and remission. Thus, 
we observed two clinical phenotypes according to the pres-
ence or absence of anti-MCV or anti-CCP2 antibodies.
Pathogenic models of RA nowadays include smoking as 
a relevant trigger factor of immune reactions to autoantigens 
modified by citrullination in patients with HLA-DR shared 
epitope [2]. This is in agreement with the observed signifi-
cant association between anti-CCP2 antibodies and smoking 
status as well as disease activity in our study. Although caus-
ative association are not ideal in a cross-sectional design, we 
were not able to show an association between smoking and 
the formation of antibodies against carbamylated antigen. 
While exposure to smokes causes carbamylation at physi-
ological levels depending on the concentrations, there are 
potentially also other so far not identified triggering factors 
for the induction of carbamylation in RA [31, 34].
Taken together, combination of two tests for ACPA and 
anti-carbVIM IgM significantly increases the diagnos-
tic sensitivity for RA and provides the best performance 
achieved so far in a Cuban cohort. Thus, for anti-MCV IgG 
or anti-CCP2 seronegative patients it can be recommended 
to test for anti-carbVIM IgM. This strategy should be imple-
mented in the diagnostic of RA in Latin American countries 
and needs to be confirmed in other cohorts. Our results sup-
port the model that citrullination and carbamylation may 
contribute unidirectional to the pathogenesis of RA.
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